Evidence map›Paper›PMID 40832984›Full record

ArticleFuture oncology (London, England)2025

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma.

Lucio N Gordan, Amanda Warner, Trevor Heritage, Amy Ming, Niodita Gupta-Werner, Shuchita Kaila, Annelore Cortoos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucio N GordanFlorida Cancer Specialists & Research Institute, Tampa, FL, USA.
Amanda WarnerFlorida Cancer Specialists & Research Institute, Tampa, FL, USA.
Trevor HeritageFlorida Cancer Specialists & Research Institute, Tampa, FL, USA.
Amy MingFlorida Cancer Specialists & Research Institute, Tampa, FL, USA.
Niodita Gupta-WernerJohnson & Johnson, Horsham, PA, USA.
Shuchita KailaJohnson & Johnson, Horsham, PA, USA.
Annelore CortoosJohnson & Johnson, Horsham, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo explore community hematologist/oncologist perspectives on the patterns, drivers, and barriers of use of minimal residual disease (MRD) testing in patients with multiple myeloma (MM), and gain understanding on the use of these test results in clinical decision-making and response-adapted treatment approaches.

methodsA survey was conducted among hematologists/oncologists from a large community oncology practice network in the US who use MRD testing in the management of patients with MM.

resultsOf 22 hematologists/oncologists included, 72.7% reported being comfortable/very comfortable with MRD testing but prescribed a median of only 2.5 tests between September 2019 and October 2023. The most frequently reported driver for MRD testing was to monitor patient remission status. The logistics of sending samples to MRD testing facilities was the most frequently reported perceived barrier for MRD testing. The use of MRD test results to guide treatment decisions and further MRD monitoring varied.

conclusionThere are opportunities to reduce the barriers for the use of MRD testing and for generation of additional data on the clinical impact of these test results to support the development of guidelines and provide further education on the implementation of MRD test results in clinical practice and aid clinical decision-making.

Indexed as

Multiple MyelomaNeoplasm, ResidualOncologistsPractice Patterns, Physicians'Clinical Decision-MakingFemaleHumansMaleSurveys and Questionnairesminimal residual diseaseMRD negativityMRD testingMultiple myelomaphysician perspectivesurveytreatment decision

Identifiers

PMID40832984
PMCPMC12439568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.